December 20, 2019 – 3D Medicines, Inc. (“3D Medicines”) announced that it has signed a collaboration agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (“Alphamab”), a wholly owned subsidiary of Alphamab Oncology (Stock code: 9966.HK) and TRACON Pharmaceuticals (“TRACON”) for the clinical development and commercialization of KN035, a PD-L1 single-domain antibody, in soft tissue sarcoma in North America.